EA201790140A1 - Фармацевтические лекарственные формы - Google Patents

Фармацевтические лекарственные формы

Info

Publication number
EA201790140A1
EA201790140A1 EA201790140A EA201790140A EA201790140A1 EA 201790140 A1 EA201790140 A1 EA 201790140A1 EA 201790140 A EA201790140 A EA 201790140A EA 201790140 A EA201790140 A EA 201790140A EA 201790140 A1 EA201790140 A1 EA 201790140A1
Authority
EA
Eurasian Patent Office
Prior art keywords
medicine forms
pharmaceutical medicine
dosage forms
pharmaceutical dosage
pharmaceutical
Prior art date
Application number
EA201790140A
Other languages
English (en)
Other versions
EA033685B1 (ru
Inventor
Стефаниа Беато
Пегги Квинтон
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201790140A1 publication Critical patent/EA201790140A1/ru
Publication of EA033685B1 publication Critical patent/EA033685B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим лекарственным формам для перорального введения, включающим лекарственное вещество 4-[(5R)-6,7-дигидро-5Н-пирроло[1,2-с]имидазол-5-ил]-3-фторбензонитрил или его любую фармацевтически приемлемую соль, и к способам изготовления указанных твердых фармацевтических лекарственных форм.
EA201790140A 2014-07-07 2015-07-06 Фармацевтические лекарственные формы EA033685B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021271P 2014-07-07 2014-07-07
PCT/IB2015/055098 WO2016005880A1 (en) 2014-07-07 2015-07-06 Pharmaceutical dosage forms

Publications (2)

Publication Number Publication Date
EA201790140A1 true EA201790140A1 (ru) 2017-05-31
EA033685B1 EA033685B1 (ru) 2019-11-15

Family

ID=53610933

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201991359A EA201991359A1 (ru) 2014-07-07 2015-07-06 Фармацевтические лекарственные формы
EA201790140A EA033685B1 (ru) 2014-07-07 2015-07-06 Фармацевтические лекарственные формы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201991359A EA201991359A1 (ru) 2014-07-07 2015-07-06 Фармацевтические лекарственные формы

Country Status (29)

Country Link
US (2) US10143680B2 (ru)
EP (2) EP3166596B1 (ru)
JP (2) JP6731136B2 (ru)
KR (1) KR102468610B1 (ru)
CN (1) CN106470704B (ru)
AR (1) AR101116A1 (ru)
AU (1) AU2015287336B2 (ru)
BR (1) BR112016030243B1 (ru)
CA (1) CA2954393C (ru)
CL (1) CL2017000026A1 (ru)
CY (1) CY1120749T1 (ru)
DK (1) DK3166596T3 (ru)
EA (2) EA201991359A1 (ru)
EC (1) ECSP17008187A (ru)
ES (1) ES2686704T3 (ru)
HR (1) HRP20181406T1 (ru)
HU (1) HUE039037T2 (ru)
IL (1) IL249374B (ru)
LT (1) LT3166596T (ru)
MX (1) MX2016017315A (ru)
PE (1) PE20170201A1 (ru)
PH (1) PH12016502540A1 (ru)
PL (1) PL3166596T3 (ru)
PT (1) PT3166596T (ru)
SG (1) SG11201610227TA (ru)
SI (1) SI3166596T1 (ru)
TN (1) TN2016000557A1 (ru)
TW (1) TWI707682B (ru)
WO (1) WO2016005880A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020011471A (es) 2018-05-03 2020-12-07 Damian Pharma Ag R-fadrozol para usar en el tratamiento de aldosteronismo.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191487A1 (en) 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
TW200900094A (en) * 2007-03-13 2009-01-01 Takeda Pharmaceutical Solid preparation
SG182393A1 (en) * 2010-01-14 2012-08-30 Novartis Ag Use of an adrenal hormone-modifying agent
US20120064157A1 (en) * 2010-08-27 2012-03-15 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2013036563A1 (en) * 2011-09-08 2013-03-14 Novartis Ag Pharmaceutical compositions comprising an aromatase inhibitor
JP5749410B2 (ja) 2012-01-17 2015-07-15 ノバルティス アーゲー ジヒドロピロロ［１，２−ｃ］イミダゾリルアルドステロンシンターゼまたはアロマターゼ阻害薬の新たな形態および塩
WO2013126326A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
IN2014DN09240A (ru) * 2012-04-12 2015-07-10 Novartis Ag
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

Also Published As

Publication number Publication date
HRP20181406T1 (hr) 2018-10-19
US10143680B2 (en) 2018-12-04
US20190060283A1 (en) 2019-02-28
LT3166596T (lt) 2018-09-25
HUE039037T2 (hu) 2018-12-28
EA033685B1 (ru) 2019-11-15
IL249374A0 (en) 2017-02-28
EP3412278A1 (en) 2018-12-12
AU2015287336A1 (en) 2017-01-12
PT3166596T (pt) 2018-10-19
CY1120749T1 (el) 2019-12-11
SI3166596T1 (sl) 2018-10-30
EP3166596A1 (en) 2017-05-17
EP3166596B1 (en) 2018-06-06
JP2019194221A (ja) 2019-11-07
US10709691B2 (en) 2020-07-14
BR112016030243B1 (pt) 2023-04-11
WO2016005880A1 (en) 2016-01-14
KR20170029491A (ko) 2017-03-15
CA2954393A1 (en) 2016-01-14
CN106470704B (zh) 2020-07-31
PL3166596T3 (pl) 2018-11-30
PH12016502540A1 (en) 2017-04-10
AR101116A1 (es) 2016-11-23
CL2017000026A1 (es) 2017-07-28
IL249374B (en) 2021-09-30
KR102468610B1 (ko) 2022-11-21
CN106470704A (zh) 2017-03-01
CA2954393C (en) 2022-07-19
MX2016017315A (es) 2017-04-27
TWI707682B (zh) 2020-10-21
DK3166596T3 (en) 2018-09-10
SG11201610227TA (en) 2017-01-27
ES2686704T3 (es) 2018-10-19
TW201613586A (en) 2016-04-16
BR112016030243A2 (pt) 2017-08-22
JP6731136B2 (ja) 2020-07-29
US20170202808A1 (en) 2017-07-20
PE20170201A1 (es) 2017-04-08
EA201991359A1 (ru) 2020-03-13
AU2015287336B2 (en) 2018-06-14
JP2017520590A (ja) 2017-07-27
ECSP17008187A (es) 2018-03-31
TN2016000557A1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
EA201990519A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2021010306A (es) Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso.
EA201891099A1 (ru) 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201692436A1 (ru) Медицинское применение
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
EA201792591A1 (ru) Фармацевтические препараты
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
EA201691231A1 (ru) Фармацевтические лекарственные формы
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
CY1120749T1 (el) Φαρμακευτικες δοσολογικες μορφες
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
EA201691599A1 (ru) Комбинация таурина и рацеметионина для лечения заболеваний печени
EA201200799A1 (ru) Гепатопротекторное средство

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ